Phibro Animal Health (NASDAQ:PAHC) had its target price boosted by analysts at Morgan Stanley from $30.00 to $36.00 in a report released on Wednesday. The firm presently has an “underweight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 1.84% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on the company. Credit Suisse Group upped their price objective on Phibro Animal Health from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Tuesday. BidaskClub cut Phibro Animal Health from a “sell” rating to a “strong sell” rating in a report on Friday, January 26th. Zacks Investment Research upgraded Phibro Animal Health from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Piper Jaffray Companies restated a “buy” rating and set a $42.00 target price on shares of Phibro Animal Health in a report on Friday, November 10th. Finally, ValuEngine cut Phibro Animal Health from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $38.20.

Phibro Animal Health (NASDAQ:PAHC) opened at $35.35 on Wednesday. Phibro Animal Health has a fifty-two week low of $26.70 and a fifty-two week high of $40.25. The company has a quick ratio of 1.85, a current ratio of 3.12 and a debt-to-equity ratio of 1.82. The stock has a market capitalization of $1,470.70, a PE ratio of 23.17, a PEG ratio of 4.07 and a beta of 1.18.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Monday, February 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.06. Phibro Animal Health had a return on equity of 40.49% and a net margin of 7.90%. The firm had revenue of $205.90 million during the quarter, compared to analysts’ expectations of $194.90 million. During the same period in the prior year, the business earned $0.39 EPS. The company’s revenue for the quarter was up 7.5% compared to the same quarter last year. research analysts anticipate that Phibro Animal Health will post 1.65 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. boosted its holdings in Phibro Animal Health by 59.0% during the 3rd quarter. Prudential Financial Inc. now owns 141,760 shares of the company’s stock valued at $5,253,000 after acquiring an additional 52,590 shares during the period. Janus Henderson Group PLC purchased a new stake in Phibro Animal Health during the 2nd quarter valued at about $6,353,000. Magnetar Financial LLC bought a new position in Phibro Animal Health during the 3rd quarter valued at approximately $605,000. California Public Employees Retirement System raised its position in Phibro Animal Health by 9.5% during the 3rd quarter. California Public Employees Retirement System now owns 44,994 shares of the company’s stock valued at $1,667,000 after purchasing an additional 3,894 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Phibro Animal Health by 5.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 416,001 shares of the company’s stock valued at $15,413,000 after purchasing an additional 19,994 shares during the last quarter. Institutional investors own 48.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Phibro Animal Health (PAHC) Price Target Increased to $36.00 by Analysts at Morgan Stanley” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/phibro-animal-health-pahc-price-target-increased-to-36-00-by-analysts-at-morgan-stanley.html.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.